The Effect of Therapeutic Anticoagulation on Overall Survival in Men Receiving First-Line Docetaxel Chemotherapy for Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2014.04.008
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

Cabazitaxel in the Management of Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel-Based Chemotherapy

European Oncology and Haematology
OncologyHematology
2012English

Treatment Sequences, Patient Characteristics, and Overall Survival of Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer in the Community Setting

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

LINE-1 as a Therapeutic Target for Castration-Resistant Prostate Cancer

Frontiers in Bioscience - Landmark
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2018English

Outcome of Combination Chemotherapy With Docetaxel, Estramustine Phosphate, and Carboplatin After Docetaxel and Prednisolone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Journal of Cancer Therapy
2016English

Predictive Factors of Response and Overall Survival in Patients With Castration-Resistant Metastatic Prostate Cancer Undergoing177Lu-Psma Therapy

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-Resistant Prostate Cancer After Chemotherapy

Klinicka Onkologie
Oncology
2016English

Pcn336 - Treatment of Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With Docetaxel in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer

JAMA Oncology
Cancer ResearchOncology
2018English

Phase II Randomized Study of Figitumumab Plus Docetaxel and Docetaxel Alone With Crossover for Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy